Clinical Scorecard: Clinical Features and Management Difficulties in Pediatric Patients with Classic Congenital Adrenal Hyperplasia Resulting from 21-Hydroxylase Deficiency

At a Glance

Key Highlights

• Classic CAH presents with adrenal insufficiency, salt-wasting, and virilization, especially in 46,XX infants with genital differences.
• Newborn screening using 17-hydroxyprogesterone assays standardized by gestational age is critical for early diagnosis and prevention of morbidity and mortality.
• Treatment includes glucocorticoid replacement to suppress excess androgens and mineralocorticoid therapy with fludrocortisone plus salt supplementation, with monitoring of growth and hormone levels.

Guideline-Based Recommendations

Diagnosis

• Perform newborn screening with 17-hydroxyprogesterone assays standardized by gestational age using automated immunoassays.
• Confirm positive newborn screens with referral to pediatric endocrinology and further biochemical testing including LC-MS/MS measurement of 17-OHP and cosyntropin stimulation test.
• Use cosyntropin stimulation with a complete adrenal steroid profile to differentiate 21OHD from other enzymatic defects.

Management

• Initiate glucocorticoid therapy to replace cortisol and suppress ACTH-driven androgen excess.
• Administer mineralocorticoid therapy (fludrocortisone) and provide appropriate salt intake, especially in salt-wasting forms.
• Adjust mineralocorticoid therapy based on severity; some mild cases may not require fludrocortisone after infancy.

Monitoring & Follow-up

• Regular anthropometric measurements and laboratory monitoring of adrenal steroid precursors and electrolytes.
• Monitor for complications including premature adrenarche, precocious puberty, early growth plate closure, hypertension, and overweight/obesity.
• Psychosocial and surgical considerations for genital differences, with communication strategies for children and families.

Risks

• Risk of salt-wasting crisis and early neonatal morbidity and mortality if diagnosis is missed or delayed.
• High false positive rates in newborn screening necessitate confirmatory testing.
• Potential misclassification of severely virilized 46,XX infants as 46,XY leading to diagnostic delays.

Patient & Prescribing Data

Infants and children diagnosed with classic CAH due to 21OHD

Glucocorticoid and mineralocorticoid replacement tailored to enzyme activity severity; mineralocorticoid therapy may be discontinued in mild cases after infancy; treatment aims to balance hormone replacement and suppression of androgen excess.

Clinical Best Practices

• Implement universal newborn screening for 21OHD with gestational age–adjusted 17-OHP assays.
• Refer positive screens promptly to pediatric endocrinologists for confirmatory testing and treatment initiation.
• Use LC-MS/MS for confirmatory and follow-up testing to improve specificity.
• Provide multidisciplinary care including endocrinology, psychosocial support, and surgical consultation as needed.
• Educate families and caregivers on the nature of CAH, treatment goals, and communication about bodily differences.

References

• Endocrine Society Clinical Practice Guidelines on CAH
• Newborn Screening for 21-Hydroxylase Deficiency